Next Article in Journal
Human FBXL8 Is a Novel E3 Ligase Which Promotes BRCA Metastasis by Stimulating Pro-Tumorigenic Cytokines and Inhibiting Tumor Suppressors
Previous Article in Journal
Electroporation-Based Treatments in Urology
Article

Therapeutic Potential of Chemically Modified miR-489 in Triple-Negative Breast Cancers

1
Department of Pathology, Stony Brook Medicine, Stony Brook, NY 11794, USA
2
Department of Life Sciences, Ewha Womans University, Seoul 03760, Korea
3
Department of Pharmacological Sciences, Stony Brook Medicine, Stony Brook, NY 11794, USA
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Cancers 2020, 12(8), 2209; https://doi.org/10.3390/cancers12082209
Received: 22 June 2020 / Revised: 27 July 2020 / Accepted: 3 August 2020 / Published: 7 August 2020
Triple-negative breast cancers (TNBCs) lack ER, PR and her2 receptors that are targets of common breast cancer therapies with poor prognosis due to their high rates of metastasis and chemoresistance. Based on our previous studies that epigenetic silencing of a potential metastasis suppressor, arrestin domain-containing 3 (ARRDC3), is linked to the aggressive nature of TNBCs, we identified a sub-group of tumor suppressing miRNAs whose expressions were significantly up-regulated by ARRDC3 over-expression in TNBC cells. Among these tumor suppressing miRs, we found that miR-489 is most anti-proliferative in TNBC cells. miR-489 also blocked DNA damaging responses (DDRs) in TNBC cells. To define the mechanism by which miR-489 inhibits TNBC cell functions, we screened the potential target genes of miR-489 and identified MDC-1 and SUZ-12 as novel target genes of miR-489 in TNBC cells. To further exploit the therapeutic potentials of miR-489 in TNBC models, we chemically modified the guide strand of miR-489 (CMM489) by replacing Uracil with 5-fluorouracil (5-FU) so that tumor suppressor (miR-489) and DNA damaging (5-FU) components are combined into a single agent as a novel drug candidate for TNBCs. Our studies demonstrated that CMM489 shows superior effects over miR-489 or 5-FU in inhibition of TNBC cell proliferation and tumor progression, suggesting its therapeutic efficacy in TNBC models. View Full-Text
Keywords: ARRDC3; miR-489; CMM489; chemoresistance; triple-negative breast cancers ARRDC3; miR-489; CMM489; chemoresistance; triple-negative breast cancers
Show Figures

Figure 1

MDPI and ACS Style

Soung, Y.H.; Chung, H.; Yan, C.; Fesler, A.; Kim, H.; Oh, E.-S.; Ju, J.; Chung, J. Therapeutic Potential of Chemically Modified miR-489 in Triple-Negative Breast Cancers. Cancers 2020, 12, 2209. https://doi.org/10.3390/cancers12082209

AMA Style

Soung YH, Chung H, Yan C, Fesler A, Kim H, Oh E-S, Ju J, Chung J. Therapeutic Potential of Chemically Modified miR-489 in Triple-Negative Breast Cancers. Cancers. 2020; 12(8):2209. https://doi.org/10.3390/cancers12082209

Chicago/Turabian Style

Soung, Young H., Heesung Chung, Cecilia Yan, Andrew Fesler, Hyungjin Kim, Eok-Soo Oh, Jingfang Ju, and Jun Chung. 2020. "Therapeutic Potential of Chemically Modified miR-489 in Triple-Negative Breast Cancers" Cancers 12, no. 8: 2209. https://doi.org/10.3390/cancers12082209

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop